ABSTRACT

Introduction

Migraine is one of the most common illnesses in the world, with severe economical and subjective implications. Nowadays specific and nonspecific drugs are used for migraine chronic therapy, but a portion of patients have no benefit from these administrations. CGRP receptor antagonists are a good preventive treatment for episodic and chronic migraine.

Areas covered

This article reviews both preclinical and clinical studies on eptinezumab as a potential preventive therapy for migraine, as well as pharmacokinetic and pharmacodynamic features. Thus, it summarizes safety and tolerability data based on human studies.

Expert opinion

Eptinezumab had good results in several trials, making this molecule a promising migraine preventive drug. Although preclinical and clinical studies showed a significant efficacy, there are no data on the use of Eptinezumab during pregnancy or breastfeeding. There are still some knowledge limits about its pharmacokinetics and metabolism. This is a matter of concern that should be addressed in future studies.

中文翻译：

---

依替尼单抗治疗偏头痛

摘要

介绍

偏头痛是世界上最常见的疾病之一，具有严重的经济和主观影响。如今，特异性和非特异性药物用于偏头痛慢性治疗，但部分患者无法从这些给药中获益。CGRP 受体拮抗剂是发作性和慢性偏头痛的良好预防性治疗。

涵盖的领域

本文回顾了依替尼单抗作为一种潜在的偏头痛预防疗法的临床前和临床研究，以及药代动力学和药效学特征。因此，它总结了基于人体研究的安全性和耐受性数据。

专家意见

依替尼单抗在多项试验中取得了良好的效果，使该分子成为一种很有前途的偏头痛预防药物。尽管临床前和临床研究显示了显着疗效，但没有关于在怀孕或哺乳期间使用依替尼单抗的数据。关于其药代动力学和代谢仍存在一些知识局限。这是一个值得关注的问题，应该在未来的研究中解决。